Evotec's Surprise Beat Draws a Ten-Euro Bull and a 3.60-Euro Hold — With Guidance Left Untouched
Published on 10/20/2026 at 14:20 | Editorial boerse-global.de
Evotec has given investors a rare thing: a set of interim figures that came in ahead of consensus. What it has not given them is a reason to re-rate the stock, at least not according to the two research houses that have weighed in since. The gap between those two verdicts — one at €10, one at €3.60 — says as much about the ambiguity of the beat as about Evotec itself.
Two houses, two very different numbers
Berenberg restated its "Hold" rating and €3.60 price target on Friday, acknowledging the stronger-than-expected results without shifting its recommendation or its valuation. RBC Capital Markets had done much the same a day earlier in spirit, though not in substance: on 14 October it reaffirmed "Outperform" with a €10 target. Neither firm moved its marker after the preliminary release.
That leaves a spread of roughly €6.40 between the two views of the same set of numbers. Neither house issued a joint rationale, and the unchanged ratings offer no shared explanation — only a reminder that a positive deviation from expectations does not, on its own, trigger fresh price targets.
The company's own explanation: timing, not transformation
Evotec itself attributed the gap to consensus mainly to the timing of when estimates were compiled. That framing matters, because it caps how much the beat can be read into the full year. Better interim numbers and a raised annual forecast are not the same thing, and Evotec made no move toward the latter.
Should investors sell immediately? Or is it worth buying Evotec?
For the first nine months of 2026, the company expects group revenue of around €465.0m and an adjusted group EBITDA of roughly -€42.8m. The figures are unaudited. Full-year guidance stands exactly where it did before: revenue of €570m to €610m, and adjusted EBITDA of -€70m to -€105m.
Context for that caution arrived via Reuters, which pointed back to July's guidance cut. Delayed milestone payments and partnerships that closed later than planned weighed on the outlook at the time. That history explains why the timing of both business and expectations carries outsized weight in how the stock is valued.
Where the bulls and the cautious actually agree
The adjusted EBITDA line is the hinge on which both cases turn. At around -€42.8m for the nine months, the result beat market expectations — Evotec said as much, and RBC analyst Charles Weston cited both the revenue and EBITDA overshoot alongside the confirmed annual guidance on 14 October. Berenberg's Christian Ehmann, for his part, flagged tailwind from the research and preclinical development business and called the results surprisingly strong.
Yet a beat and a loss can coexist. The improved figure is an argument for the equity; the negative sign in front of it is a reminder that operational recovery has not yet produced positive adjusted EBITDA. Both statements hold at once, and the unchanged full-year range of -€70m to -€105m keeps the second one in view.
The bull case, then, is not that Evotec has cleared every hurdle. It is that stronger operating performance combined with a reaffirmed outlook could rebuild confidence — provided the research-business tailwind proves more durable than a single favourable quarter. The bear case does not require a new profit warning. Details in the full results that fail to show a credible continuation of operating strength would be enough to undercut the more optimistic reading.
Evotec at a turning point? This analysis reveals what investors need to know now.
A new face in the lab
Alongside the numbers, Evotec moved on the scientific side. On Thursday the company named Dr. Joanna Holbrook as Chief Scientific Officer and a member of the management board, tasked with leading global scientific strategy. Holbrook joins from Novo Nordisk, and her start date is set for 1 November.
The appointment shapes the company's future research direction; the near-term financial read, for now, still rests on the confirmed annual targets.
5 November is the real test
Evotec will publish full results for the third quarter and the first nine months of 2026 on 5 November 2026. That date is the next concrete catalyst, and it carries more weight than a simple confirmation of the preliminary figures. What matters is how convincingly management explains the operating trajectory behind them — and that, in turn, will determine which of the two very different analyst perspectives rests on firmer ground.
Ad
Evotec Stock: New Analysis - 20 October
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
